We are initiating coverage of Bright Minds Biosciences with a Buy rating, as we believe the stock is undervalued. We see a key catalyst in the Phase 2 data readout for BMB-101, which is expected in Q2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results